FOXO TECHNOLOGIES INC.

FOXO Technologies Inc. (Nasdaq: FOXO) is an insurtech company applying epigenetic biomarker science to life insurance underwriting and distribution. The company went public in 2022 through a SPAC transaction with CF Acquisition Corp. VIII, a blank-check vehicle sponsored by Cantor Fitzgerald. Operating at the intersection of longevity science and health technology, FOXO aims to modernize how life insurers assess biological age and mortality risk using saliva-based epigenetic testing rather than traditional actuarial methods. The company filed a Form 10-Q with the SEC on August 12, 2022, reflecting its reporting obligations as a newly public entity in the insurtech sector. For comprehensive filing history, sponsor data, and SPAC deal analytics on FOXO and thousands of other transactions, sign up for full access at SpacDesk.